SCHEMBL11900516

SCHEMBL11900516

COc1cnc(-c2ccccn2)nc1Oc1ccccc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 8/20 1.00
▸ LMNA P02545 5/20 1.00
▸ SMN1; SMN2 Q16637 5/20 1.00
▸ ALDH1A1 P00352 5/20 0.87
▸ TDP1 Q9NUW8 1/20 0.87
▸ KMT2A Q03164 8/20 0.81
▸ MEN1 O00255 7/20 0.81
▸ POLB P06746 2/20 0.81
▸ PPP1CA P62136 3/20 0.76
▸ TRPM8 Q7Z2W7 3/20 0.67
▸ MAPT P10636 7/20 0.66
▸ CYP1A2 P05177 2/20 0.66
▸ CYP2C9 P11712 2/20 0.66
▸ CYP2C19 P33261 2/20 0.66
▸ CYP3A4 P08684 1/20 0.66
▸ KDM4E B2RXH2 1/20 0.59
▸ HTT P42858 1/20 0.59
▸ NPSR1 Q6W5P4 2/20 0.57
▸ GAA P10253 1/20 0.57
▸ MITF O75030 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10270667 0.81 TRPM8 (1.00) L3MBTL1LMNASMN1; SMN2ALDH1A1TDP1
SCHEMBL10270342 0.77 L3MBTL1 (0.65) L3MBTL1LMNASMN1; SMN2ALDH1A1TDP1
SCHEMBL1443064 0.77 L3MBTL1 (0.65) L3MBTL1LMNASMN1; SMN2ALDH1A1TDP1
SCHEMBL1442223 0.77 LMNA (0.67) L3MBTL1LMNASMN1; SMN2ALDH1A1TDP1
SCHEMBL23837648 0.74 TRPM8 (0.73) L3MBTL1LMNASMN1; SMN2ALDH1A1TDP1
SCHEMBL1443569 0.74 L3MBTL1 (1.00) L3MBTL1LMNASMN1; SMN2ALDH1A1TDP1
SCHEMBL1443857 0.73 L3MBTL1 (0.59) L3MBTL1LMNASMN1; SMN2ALDH1A1TDP1
SCHEMBL1442979 0.73 MEN1 (1.00) L3MBTL1LMNASMN1; SMN2ALDH1A1TDP1
SCHEMBL8779911 0.72 L3MBTL1 (0.56) L3MBTL1LMNASMN1; SMN2ALDH1A1TDP1
SCHEMBL3245836 0.71 L3MBTL1 (0.58) L3MBTL1LMNASMN1; SMN2ALDH1A1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2473486-B2 PYRIMIDINES AS HEPCIDINE ANTAGONISTS VIFOR INT AG (CH) 2021-09-22 — — EP disclosed
EP-2473486-B2 PYRIMIDINES AS HEPCIDINE ANTAGONISTS VIFOR INT AG (CH) 2021-09-22 — — EP disclosed
EP-2473486-B1 PYRIMIDINES AS HEPCIDINE ANTAGONISTS VIFOR INT AG (CH) 2015-10-28 — — EP disclosed
EP-2473486-B1 PYRIMIDINES AS HEPCIDINE ANTAGONISTS VIFOR INT AG (CH) 2015-10-28 — — EP disclosed
US-20120202806-A1 Novel Pyrimidine- And Triazine-Hepcidine Antagonists VIFOR (INTERNATIONAL) AG (CH) 2012-08-09 — — US disclosed
US-20120202806-A1 Novel Pyrimidine- And Triazine-Hepcidine Antagonists VIFOR (INTERNATIONAL) AG (CH) 2012-08-09 — — US disclosed
US-20120202806-A1 Novel Pyrimidine- And Triazine-Hepcidine Antagonists VIFOR (INTERNATIONAL) AG (CH) 2012-08-09 — — US disclosed
WO-2011026835-A1 NOVEL PYRIMIDINE AND TRIAZINE HEPCIDINE ANTAGONISTS VIFOR (INTERNATIONAL) AG (CH) 2011-03-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120202806-A1 Novel Pyrimidine- And Triazine-Hepcidine Antagonists HAMP, DHPS, SLC40A1 L3MBTL1 3829/4885LMNA 4333/4885SMN1; SMN2 4562/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback